Literature DB >> 16524668

Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine.

Alexander M Ponizovsky1, Alexander Grinshpoon, Anatoly Margolis, Rami Cohen, Paula Rosca.   

Abstract

Previous studies comparing buprenorphine and clonidine provided little information about subjective factors associated with the effective management of opioid withdrawal. This study sought to compare detoxification programs using these medications with regard to side-effects and related distress, general well-being, perceived self-efficacy and social support. A total of 200 treatment-seeking heroin-dependent patients, aged 18-50, were randomly assigned to buprenorphine or clonidine inpatient withdrawal treatments over 10days followed by 11days of relapse prevention measures. A semi-structured interview and a battery of self-rating scales assessing parameters of the interest were administered to the patients who completed the 10-day detoxification protocol with buprenorphine (n=90) and clonidine (n=50). Chi-square statistics and analysis of covariance were performed to examine between-group differences. Compared with patients treated with clonidine, patients who received buprenorphine developed significantly less side-effects and related distress, and had higher senses of well-being, self-efficacy and social support. The findings suggest that buprenorphine is preferable for inpatient detoxification due to its side-effects profile and positive effects on well-being and psychosocial variables. These early benefits of buprenorphine could enable consequent maintenance treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16524668     DOI: 10.1016/j.addbeh.2006.01.014

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  4 in total

1.  Heroin refusal self-efficacy and preference for medication-assisted treatment after inpatient detoxification.

Authors:  Shannon R Kenney; Genie L Bailey; Bradley J Anderson; Michael D Stein
Journal:  Addict Behav       Date:  2017-05-09       Impact factor: 3.913

2.  Trends in opioid analgesics consumption, Israel, 2000-2008.

Authors:  Alexander M Ponizovsky; Eli Marom; Alexander Zeldin; Nathan I Cherny
Journal:  Eur J Clin Pharmacol       Date:  2010-11-06       Impact factor: 2.953

3.  Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.

Authors:  Sudie E Back; Rebecca L Payne; Amy Herrin Wahlquist; Rickey E Carter; Zachary Stroud; Louise Haynes; Maureen Hillhouse; Kathleen T Brady; Walter Ling
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

Review 4.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.